Genetic Metabolic Disorders Research Unit
Using cutting edge genetic technologies, we have discovered a number of disease genes for rare genetic disorders, some of which are world firsts, some of which led to institution of specific therapies, and all of which have improved our understanding of the genetic risks to other family members.
Based on our improved understanding of the biology of Rett syndrome, we are now embarking on a preclinical trial of a potentially new therapy for this devastating neurological disorder.
We have developed a new approach to treating the inborn error of metabolism, phenylketonuria (PKU). All babies in Australia are screened for PKU. Our new therapy, a genetically modified probiotic, is currently undergoing preclinical trials, and is showing promising results. This research is being undertaken in collaboration with Associate Professor Kevin Carpenter from the NSW Biochemical Genetics Service.